Covid-19 Research

Research Article

Rapid HbA1c Reduction May Reduce Diabetes-Related Complications in Patients with Severe Hyperglycemia

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Research Article
Subject Medicine Group
OCLC JBRES Record
Ying-Yun Ou-Yang and Harn-Shen Chen*
Issue: Volume5-Issue10
Pages: 1379-1387
Received: 2024-10-17
Accepted: 2024-10-25
Published: 2024-10-27

Abstract

Aims: To investigate whether a rapid reduction in HbA1c is more effective for reducing diabetes-related complications and mortality than a gradual approach in patients with severe hyperglycemia.

Methods: This retrospective cohort study included 577 patients with type 2 diabetes and an initial HbA1c level ≥ 9.0%, recruited from the Diabetes Shared Care Program at the Taipei Veterans General Hospital from January 2004 to December 2015 and followed up until December 2019. Participants were divided into two groups based on the rate of HbA1c reduction: rapid (HbA1c level < 9.4% by month 3) and slow (HbA1c level ≥ 9.4% by month 3). Primary outcomes were nephropathy, retinopathy, and all-cause mortality. Data were analyzed using Cox proportional hazards models, adjusted for potential confounders.

Results: The rapid-reduction group exhibited significantly lower mean HbA1c levels over five years and risk of all-cause mortality (Hazard Ratio [HR]: 1.371; 95% CI: 1.026-1.833; p = 0.033) than the slow-reduction group. In the subgroup without substantial baseline diabetes-related complications, the rapid-reduction group had lower risks of urine albumin/creatinine ratio ≥ 300 mg/g (HR: 1.441; 95% CI: 1.011-2.055; p = 0.043), any retinopathy (HR: 1.497; 95% CI: 1.079-2.076; p = 0.016), and all-cause mortality (HR: 1.456; 95% CI: 1.034-2.050; p = 0.031) than the slow-reduction group.

Conclusion: Rapid reduction of HbA1c levels significantly reduces risk of all-cause mortality in patients with severe hyperglycemia. It also reduces risk of nephropathy and retinopathy in patients without substantial diabetes-related complications at baseline.

FullText HTML FullText PDF DOI: 10.37871/jbres2026 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2024 Ou-Yang YY, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Ou-Yang YY, Chen HS. Rapid HbA1c Reduction May Reduce Diabetes-Related Complications in Patients with Severe Hyperglycemia. J Biomed Res Environ Sci. 2024 Oct 27; 5(10): 1379-1387. doi: 10.37871/jbres2026, Article ID: JBRES2026, Available at: https://www.jelsciences.com/articles/jbres2026.pdf

Subject area(s)

MetabolismDiabetesClinical Endocrinology

References

  1. Mitsios JP, Ekinci EI, Mitsios GP, Churilov L, Thijs V. Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2018 May 17;7(11):e007858. doi: 10.1161/JAHA.117.007858. PMID: 29773578; PMCID: PMC6015363.
  2. Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. Microvascular Complications of Type 2 Diabetes Mellitus. Curr Vasc Pharmacol. 2020;18(2):117-124. doi: 10.2174/1570161117666190502103733. PMID: 31057114.
  3. Eid SA, Rumora AE, Beirowski B, Bennett DL, Hur J, Savelieff MG, Feldman EL. New perspectives in diabetic neuropathy. Neuron. 2023 Sep 6;111(17):2623-2641. doi: 10.1016/j.neuron.2023.05.003. Epub 2023 May 31. PMID: 37263266; PMCID: PMC10525009.
  4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10. PMID: 18784090.
  5. Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, Heller S, MacMahon S, Mancia G, Marre M, Matthews D, Neal B, Poulter N, Rodgers A, Williams B, Zoungas S; ADVANCE-ON Collaborative Group. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care. 2016 May;39(5):694-700. doi: 10.2337/dc15-2322. Epub 2016 Mar 22. PMID: 27006512.
  6. Charu V, Liang JW, Chertow GM, Li J, Montez-Rath ME, Geldsetzer P, de Boer IH, Tian L, Tamura MK. Heterogeneous Treatment Effects of Intensive Glycemic Control on Kidney Microvascular Outcomes and Mortality in ACCORD. J Am Soc Nephrol. 2024 Feb 1;35(2):216-228. doi: 10.1681/ASN.0000000000000272. Epub 2023 Dec 11. PMID: 38073026; PMCID: PMC10843221.
  7. Zoccali C, Mallamaci F, Tripepi G, Fu EL, Stel VS, Dekker FW, Jager KJ. The long-term benefits of early intensive therapy in chronic diseases-the legacy effect. Clin Kidney J. 2023 Aug 10;16(11):1917-1924. doi: 10.1093/ckj/sfad186. PMID: 37915902; PMCID: PMC10616475.
  8. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6. PMID: 18539916.
  9. ACCORD Study Group; Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. doi: 10.1016/j.amjcard.2007.03.003. Epub 2007 Apr 16. PMID: 17599422.
  10. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010 Aug 7;376(9739):419-30. doi: 10.1016/S0140-6736(10)60576-4. Epub 2010 Jun 30. Erratum in: Lancet. 2010 Oct 30;376(9751):1466. PMID: 20594588; PMCID: PMC4123233.
  11. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39. doi: 10.1056/NEJMoa0808431. Epub 2008 Dec 17. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1028. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1024-5. doi: 10.1056/NEJMc096250. PMID: 19092145.
  12. Kahal H, Halama A, Aburima A, Bhagwat AM, Butler AE, Graumann J, Suhre K, Sathyapalan T, Atkin SL. Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects. Sci Rep. 2020 Jun 19;10(1):10233. doi: 10.1038/s41598-020-66189-1. Erratum for: Sci Rep. 2020 Mar 16;10(1):4750. doi: 10.1038/s41598-020-61531-z. PMID: 32561766; PMCID: PMC7305170.
  13. Wang J, Alexanian A, Ying R, Kizhakekuttu TJ, Dharmashankar K, Vasquez-Vivar J, Gutterman DD, Widlansky ME. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):712-20. doi: 10.1161/ATVBAHA.111.227389. Epub 2011 Dec 29. PMID: 22207730; PMCID: PMC3319449.
  14. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008 Jul-Aug;24(5):353-63. doi: 10.1002/dmrr.865. PMID: 18461635.
  15. Sheng CS, Tian J, Miao Y, Cheng Y, Yang Y, Reaven PD, Bloomgarden ZT, Ning G. Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial. Diabetes Care. 2020 Jun;43(6):1185-1190. doi: 10.2337/dc19-2589. Epub 2020 Mar 30. PMID: 32229597.
  16. Wu TE, Su YW, Chen HS. Mean HbA1c and HbA1c variability are associated with differing diabetes-related complications in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2022 Oct;192:110069. doi: 10.1016/j.diabres.2022.110069. Epub 2022 Sep 5. PMID: 36067915.
  17. Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK, Heatlie G, Loke Y, Rutter MK, Mamas MA. Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis. Diabetes Care. 2015 Dec;38(12):2354-69. doi: 10.2337/dc15-1188. PMID: 26604281.
  18. Chen J, Yi Q, Wang Y, Wang J, Yu H, Zhang J, Hu M, Xu J, Wu Z, Hou L, Zhang Z, Zhang Y, Wang Y, Tu Z, Yang K, Guo K, Zhou Y, Geng T, Pan X, Liu G, Song P, Pan A. Long-term glycemic variability and risk of adverse health outcomes in patients with diabetes: A systematic review and meta-analysis of cohort studies. Diabetes Res Clin Pract. 2022 Oct;192:110085. doi: 10.1016/j.diabres.2022.110085. Epub 2022 Sep 17. PMID: 36126799.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership